Latanoprost-induced cystoid macular oedema (CMO) is well documented, and stopping the drops before or after cataract surgery has been used to reduce this risk.1 What is not clear is whether cataract surgery can increase the risk of prostaglandin-induced CMO, following recovery from cataract surgery. In this context, we report a case of latanoprost-induced CMO developing 30 months after an uneventful cataract surgery.

An 83-year-old male patient with primary open-angle glaucoma on latanoprost (0.005%) and brinzolamide (1%) eye drops in both eyes underwent phacoemulsification with posterior chamber intraocular lens implanted in the left eye and achieved best-corrected visual acuity of 6/6. Latanoprost eye drops were continued before and after the surgery. After 3 months, the visual acuity in the operated eye dropped to 6/18 and cystoid macular oedema (CMO) was seen clinically. He was in good general health and did not suffer from diabetes mellitus. Latanoprost drops were immediately withdrawn and subtenon's triamcinolone injection was administered. The CMO resolved and the visual acuity improved to 6/9. After 4 months, a trabeculectomy with mitomycin-C (0.4 mg/ml) was carried out in the same eye. The postoperative course was uneventful, and all the antiglaucoma medications in that eye were stopped. After 5 months, needling of the bleb with 5-fluorouracil (5 mg/0.1 ml) was performed. The IOP remained high and the patient was instructed to use brinzolamide eye drops in both eyes and latanoprost eye drops in the right, nonoperated, eye.

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD